Amphivena Therapeutics, Inc. is a clinical-stage, immuno-oncology company with a novel platform of T cell engagers (Amphivena ReSTORE™) that directly targets myeloid derived suppressor cells (MDSC), thus relieving cancer-induced immune suppression while controlling cytokine release syndrome (CRS).
Employees: 11-50
Total raised: $62M
Founded date: 2012
Investors 3
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | Korys | korys.be |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.09.2019 | Series C | $62M | - |
Mentions in press and media 10
| Date | Title | Description |
| 16.12.2020 | Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564 | |
| 09.11.2020 | Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting | |
| 17.12.2019 | Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio | - |
| 24.09.2019 | Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors | The company is developing a bispecific T-cell engager antibody called AMV564, which targets CD33 and CD3. Such antibodies are immunotherapies designed to work by targeting both cancer cell-surface proteins and proteins expressed on the surf... |
| 24.09.2019 | Amphivena Closes $62 Million Series C Financing | - |
| 24.09.2019 | Amphivena Closes $62M Series C Financing | Amphivena Therapeutics, Inc., a South San Francisco, CA-based clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, closed a $62m Series C financing. The round was co-led by NanoDimension and Qiming Ventu... |
| 24.09.2019 | Quiet biotech Amphivena nabs $62M funding round | Little-known and super quiet biotech Amphivena Therapeutics has grabbed a strong and healthy $62 million series C round funding haul. The Californian company, which has only issued three press releases this year (better than the one for the... |
| 24.09.2019 | Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio | - |
| 24.09.2019 | Quiet biotech Amphivena nabs $62M funding round W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Little-known and super quiet biotech Amphivena Therapeutics has grabbed a strong and healthy $62 million series C round funding haul. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scient... |
| - | Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors | A company developing a bispecific antibody that already has clinical data in blood cancers has raised more than $60 million in its latest venture capital funding round that it plans to use to advance the drug in solid tumors. South San Fran... |